International Journal of
Reproductive Biomedicine
Sun, Jun 16, 2024
[Archive]
Volume 15, Issue 6 (7-2017)
IJRM 2017, 15(6): 323-330 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ali Mohamed M S. A new strategy and system for the ex vivo ovary perfusion and cryopreservation: An innovation. IJRM 2017; 15 (6) :323-330
URL: http://ijrm.ir/article-1-835-en.html
URL: http://ijrm.ir/article-1-835-en.html
M.D. Graduate, University of Cologne, Germany , Mohammed.shehatta1@gmail.com
Full-Text [PDF 202 kb]
(749 Downloads)
| Abstract (HTML) (3016 Views)
Full-Text: (461 Views)
Introduction
Ovarian cryopreservation aims at the preservation of fertility in young women subjected to gonadotoxic anti-cancer therapy. It is also important for women undergoing hematopoietic stem cells transplantation and other reasons of premature ovarian failure. Further indications could differ from country to another, based on the available medical regulations (1, 2). Ovarian cryopreservation can be performed using the slow freezing technique, where a programmable controlled temperature change can be applied, or the vitrification technique, where the ovarian tissue is equilibrated with suitable concentrations of cryoprotectants and directly plunged into liquid nitrogen (3, 4).Recently, ovarian cryopreservation has been tried with animals and humans, applying both slow freezing and vitrification techniques, with the results of vitrification are comparable to those of slow freezing (5-22). Ovarian cryopreservation is considered important rather than mature oocyte or embryo cryopreservation because it preserves the hormonal and fertility functions following cancer therapy. In addition, the cryopreservation of oocytes or embryos is not always possible before cancer therapy in cases of prepubertal girls, hormone- sensitive tumors, or because of the lack of a partner and or enough time (23, 24).
The ovary is composed of the cortex, which is the outer part and contains tightly packed connective tissue, and the medulla, which is central and highly vascular. The majority of the follicles, in varying stages of maturation, are located in the cortex, including the primordial follicles that require the signal for further development. In the currently applied protocols, the cortex is dissected from the medulla and subjected to cryopreservation, where many primordial follicles are present. This technique is associated with less injury rather than the cryopreservation of individual oocytes and or embryos. This may be related to the smaller size and the slower metabolic rates of the primordial follicles, the absence of zona pellucida and the in-vivo follicular maturation following transplantation (25). Accordingly, the ovarian cortex is the actual part subjected to cryopreservation, following the sharp dissection from the medulla.
After the successful cancer therapy, the thawed ovarian cortex is transplanted close to the fallopian tube, allowing the in-vivo maturation of the primordial follicles and the reestablishment of the hormonal and the fertilizing functions of the ovary (26-30).
Current techniques in ovarian cryopreservation
Cryopreservation is the process, where biological materials, cells and tissues are preserved in sub-zero temperatures to be retrieved through warming in the subsequent future. At such very low temperatures, the enzymatic activities that could damage the cell are stopped. The success of the cryopreservation depends on the use of certain compounds that protect the cells (hence, called cryoprotectants) as well as the cooling rate (31).
Cryoprotectants can be divided into two major categories; Permeable cryoprotectants that have the ability to penetrate the cell membrane and, accordingly, protect against the intracellular ice formation. The use of permeable cryoprotectants is associated with significant toxicity and extra-stress on the cell during their addition and removal, before freezing and after thawing, respectively (32). Non-permeable cryoprotectants that cannot penetrate the cell membrane and, accordingly, protect against the extracellular ice formation (33).
Ovarian cryopreservation could be achieved through the slow freezing (programmable) rate or the ultra-rapid freezing rate (vitrification). Vitrification is the technique, where the cells/tissues are frozen at an ultra-rapid rate by direct plunging into liquid nitrogen, where the cells suspension change into a glass-like solidification, avoiding ice crystal formation (34). Rapid rates of freezing do not allow the permeable cryoprotectants to exert their protective actions, which essentially require slow cooling rate. Meanwhile, the non-permeable cryoprotectants stabilize the cells during the ultra-rapid freezing (35).
Slow freezing of the ovarian tissue starts with the cutting of the ovarian cortex into strips, as an initial step. An example of a protocol could be as following, where the cortical strips are suspended in a cryoprotective solution at 4oC. The strips are then to be transferred to 2-mL cryovials, containing 0.8 mL cryoprotective solution that are to be cooled in a programmable freezer from 0C to -8oC at -2oC /min, then to be cooled to -40oC at -0.3oC /min. This is followed by cooling to -140oC at -30oC /min and transfer to liquid nitrogen (-196oC) for storage.
The programmable freezing might be performed manually by placing the cryovials in the nitrogen vapor before plunging into the liquid nitrogen, where the temperature of the vapor depends on the distance between the vials and the surface of the liquid as well as on the amount of the used liquid nitrogen. However, the control of the cooling rates in this case would be difficult (36). For thawing, the cryovials are simply placed in room temperature for 2 min, and then in a 37oC water bath till the ice completely melt.
Before transplantation, the ovarian tissue is placed in plastic petri dishes containing minimal essential medium (MEM), supplemented with Glutamax, for washing. The washing is to be performed, at least, for three times (5 min each) to get rid of the cryoprotectants (36). Vitrification of the ovarian tissue starts with the cutting of the ovarian cortex into cubes, as an initial step. Two protocols could be examples for ovarian tissue vitrification;
Protocol 1, where the vitrification solution, which contains 20% dimethylsulfoxid (DMSO), 20% ethylene glycol in MEM, supplemented with 25 mg/mL human serum albumin (HSA), is used. The ovarian cubes are to be equilibrated in 25% vitrification solution for 5 min (at 4oC), followed by equilibration in 50% vitrification solution for another 5 min (at 4oC), and finally in 100% vitrification solution for 10 min (at 4oC). Following equilibration, the ovarian cubes are to be placed on an aseptic absorbent gauze to remove the remaining vitrification solution. The cubes are then transferred to a stainless steel box, partially immersed in liquid nitrogen. Now the ovarian fragments are vitrified and are to be placed in pre-cooled cryovials for long term storage in liquid nitrogen (37).
Protocol 2, where the vitrification solution is composed of 10% dimethylsulfoxid (DMSO), and 26% ethylene glycol in MEM, supplemented with 20 mg/mL HSA, 2.5% polyvinylpyrrolidone and 1 mol/L sucrose. The ovarian cubes are to be equilibrated in 25% vitrification solution (for 5 min), then in 50% vitrification solution (for 5 min), and finally in 100% vitrification solution (for 1 min), at room temperature. After equilibration, the cubes are to be placed on an aseptic absorbent gauze at room temperature, in order to remove the remaining vitrification solution. The cubes are then to be placed in open cryostraws, and to be plunged into liquid nitrogen. Now the ovarian fragments are vitrified and are to be placed in pre-cooled cryovials for long term storage in liquid nitrogen (33, 38).
For warming of the vitrified ovarian tissue, the ovarian strips or cubes are taken out from the cryovials and placed into warming solution 1 at 37oC, which is composed of 1 mol/L sucrose in MEM, supplemented with 25 mg/mL HSA. The tissue is to be incubated in this solution for about 15 sec, and then to be transferred to the warming solution 2 (which has the same composition of warming solution 1, apart from 0.5 mol/L sucrose concentration), followed by warming solution 3 (which has the same composition of warming solution 1, apart from 0.25 mol/L sucrose concentration), and warming solution 4 (which has the same composition of warming solution 1, apart from 0 mol/L sucrose concentration), for 5 min at 37oC each (33, 37, 38).
Several studies have reported successful results of transplantation of cryopreserved ovarian tissues of both techniques, with the results of vitrification being superior or, at least, comparable to those of slow freezing (33). However, and regardless of the technique of cryopreservation, there are two major problems hindering the transplantation of the ovarian tissue and limiting the graft survival; the cryoinjury in the case of cryopreservation, and the ischemic reperfusion injury.
As the ovarian cortex is composed of tightly packed connective tissue, where it depends on the underlying highly vascular ovarian medulla for getting the necessary oxygen and nutrient supplies, it takes a relative longer time (2-3 days) to re-establish adequate vascular connections with the underlying tissue following transplantation, which leads practically to some degree of follicular atrophy and failure of long term graft survival. This is why the peritoneal grafting of the ovarian tissue has been associated with better results than the subcutaneous grafting, as the revascularization in the peritoneal case is better.
However, in all cases, a large number of follicles would be ultimately lost until the neovascularization occurs, accordingly, there would be a high risk of graft failure (39, 40). Many strategies have been tried to minimize the post-transplantation ischemic ovarian damage, however, these strategies lack the standardization, the reproducibility and the long term success (41). Examples of those strategies are:
The innovative ex vivo ovary perfusion model of Shehata
In the present technique, the donor ovary, which belongs to the cancer patient herself or the matching donor for cases of ovarian failure, is removed by a laparoscopic or an open surgical approach, where the vascular pedicle of the ovary is accessed. The ovarian artery is approached as proximal as possible, and catheterized after giving off its branches. Similarly, the ovarian vein is approached as distal as possible, and catheterized before receiving its tributaries.
Now, the donor ovary can be surgically removed, while both the vascular input and output are catheterized, however, before removal, in-vivo perfusion through the catheters is to be performed for few minutes, to avoid ischemia and any risk of the microthrombi formation. The arterial and venous catheters are connected to a circuit of perfusion, composed of the following (Figure 1):
The introduced procedure starts with the surgical retrieval of the donor ovary, where vascular catheterization and immediate perfusion begins. The used perfusate can vary according to the protocol used, for instance, minimal essential medium (MEM) supplemented with HSA or human tubal fluid medium supplemented with serum substitute supplement (SSS). Further supplementation could be considered according to the used protocol, such as ascorbic acid, antioxidants, hormones, growth factors, antibiotics, heparin, etc.
The immediate and continuous perfusion minimizes the risk of the microthrombi formation, however, thrombolytic medications could be supplemented to the perfusate, in order to dissolve any formed microthrombi. At this stage, the donor ovary has not manifested significant ischemia or oxygen or nutrient deprivation, and the vascular bed is clearly accessible. In case of fresh ovary transplantation, the ovary could be kept perfused under normothermic or hypothermic conditions till transplantation and intraoperative vascular anastomosis, allowing the chance of gross and or microscopic assessment of the graft, when needed. In this case, the ischemic reperfusion injury would be significantly minimized.
However, in case the cryopreservation of the ovary is planned, the cryopreservation solution (either for slow freezing or for vitrification) can be introduced into the circuit to simultaneously fill the cleaned vascular bed of the ovary and the plastic box around the graft. This ability, together with the presence of temperature adjustors, allow the application of the cryopreservation or vitrification protocol of interest (as previously described), where at the end, the graft can be stored in liquid nitrogen.
These abilities of the system allow, as well, the application of the warming protocols (as previously described), where the graft can be further perfused till the surgical transplantation, minimizing the ischemic reperfusion injury.
95-146-4/figure_1.jpg)
Figure 1. Diagrammatic representation of the ex vivo ovary perfusion system:
As previously discussed, the whole ovary cryopreservation has been introduced and experimentally tested (41). In addition, the idea of ex vivo perfused ovary was used before in some experimental studies for the ex vivo culture of the whole ovary, in order to allow the ex vivo oocyte maturation and development (53). However, to the best of my knowledge, it is the first time to introduce the ex vivo perfusion technique as a procedure that should precede and follow the cryopreservation of the ovary, in order to overcome the obstacles that limit the success of the technique.
Moreover, the introduced system is very unique, allowing the application of both ex vivo perfusion and cryopreservation in one system, which ensures better and simultaneous delivery of the cryoprotective and warming solutions to the inside and the outside of the organ, allowing for better outcome of the procedure. Some advantages of the system are listed in table I.
Table I. Some advantages of the Shehata's system for ex vivo ovary perfusion and cryopreservation
95-146-4/table_1.jpg)
Clinical applications and intended use of the proposed system
The proposed system can be applied in the following surgical and clinical interventions:
Conflict of interest
The intellectual properties and the system included in this manuscript belong solely to the author. All rights are preserved solely for the author. Reproduction or use of any of the included intellectual properties requires the written permission of the author. No funding was provided for the development of this work. The author welcomes funding cooperation for experimental and clinical studies.
Ovarian cryopreservation aims at the preservation of fertility in young women subjected to gonadotoxic anti-cancer therapy. It is also important for women undergoing hematopoietic stem cells transplantation and other reasons of premature ovarian failure. Further indications could differ from country to another, based on the available medical regulations (1, 2). Ovarian cryopreservation can be performed using the slow freezing technique, where a programmable controlled temperature change can be applied, or the vitrification technique, where the ovarian tissue is equilibrated with suitable concentrations of cryoprotectants and directly plunged into liquid nitrogen (3, 4).Recently, ovarian cryopreservation has been tried with animals and humans, applying both slow freezing and vitrification techniques, with the results of vitrification are comparable to those of slow freezing (5-22). Ovarian cryopreservation is considered important rather than mature oocyte or embryo cryopreservation because it preserves the hormonal and fertility functions following cancer therapy. In addition, the cryopreservation of oocytes or embryos is not always possible before cancer therapy in cases of prepubertal girls, hormone- sensitive tumors, or because of the lack of a partner and or enough time (23, 24).
The ovary is composed of the cortex, which is the outer part and contains tightly packed connective tissue, and the medulla, which is central and highly vascular. The majority of the follicles, in varying stages of maturation, are located in the cortex, including the primordial follicles that require the signal for further development. In the currently applied protocols, the cortex is dissected from the medulla and subjected to cryopreservation, where many primordial follicles are present. This technique is associated with less injury rather than the cryopreservation of individual oocytes and or embryos. This may be related to the smaller size and the slower metabolic rates of the primordial follicles, the absence of zona pellucida and the in-vivo follicular maturation following transplantation (25). Accordingly, the ovarian cortex is the actual part subjected to cryopreservation, following the sharp dissection from the medulla.
After the successful cancer therapy, the thawed ovarian cortex is transplanted close to the fallopian tube, allowing the in-vivo maturation of the primordial follicles and the reestablishment of the hormonal and the fertilizing functions of the ovary (26-30).
Current techniques in ovarian cryopreservation
Cryopreservation is the process, where biological materials, cells and tissues are preserved in sub-zero temperatures to be retrieved through warming in the subsequent future. At such very low temperatures, the enzymatic activities that could damage the cell are stopped. The success of the cryopreservation depends on the use of certain compounds that protect the cells (hence, called cryoprotectants) as well as the cooling rate (31).
Cryoprotectants can be divided into two major categories; Permeable cryoprotectants that have the ability to penetrate the cell membrane and, accordingly, protect against the intracellular ice formation. The use of permeable cryoprotectants is associated with significant toxicity and extra-stress on the cell during their addition and removal, before freezing and after thawing, respectively (32). Non-permeable cryoprotectants that cannot penetrate the cell membrane and, accordingly, protect against the extracellular ice formation (33).
Ovarian cryopreservation could be achieved through the slow freezing (programmable) rate or the ultra-rapid freezing rate (vitrification). Vitrification is the technique, where the cells/tissues are frozen at an ultra-rapid rate by direct plunging into liquid nitrogen, where the cells suspension change into a glass-like solidification, avoiding ice crystal formation (34). Rapid rates of freezing do not allow the permeable cryoprotectants to exert their protective actions, which essentially require slow cooling rate. Meanwhile, the non-permeable cryoprotectants stabilize the cells during the ultra-rapid freezing (35).
Slow freezing of the ovarian tissue starts with the cutting of the ovarian cortex into strips, as an initial step. An example of a protocol could be as following, where the cortical strips are suspended in a cryoprotective solution at 4oC. The strips are then to be transferred to 2-mL cryovials, containing 0.8 mL cryoprotective solution that are to be cooled in a programmable freezer from 0C to -8oC at -2oC /min, then to be cooled to -40oC at -0.3oC /min. This is followed by cooling to -140oC at -30oC /min and transfer to liquid nitrogen (-196oC) for storage.
The programmable freezing might be performed manually by placing the cryovials in the nitrogen vapor before plunging into the liquid nitrogen, where the temperature of the vapor depends on the distance between the vials and the surface of the liquid as well as on the amount of the used liquid nitrogen. However, the control of the cooling rates in this case would be difficult (36). For thawing, the cryovials are simply placed in room temperature for 2 min, and then in a 37oC water bath till the ice completely melt.
Before transplantation, the ovarian tissue is placed in plastic petri dishes containing minimal essential medium (MEM), supplemented with Glutamax, for washing. The washing is to be performed, at least, for three times (5 min each) to get rid of the cryoprotectants (36). Vitrification of the ovarian tissue starts with the cutting of the ovarian cortex into cubes, as an initial step. Two protocols could be examples for ovarian tissue vitrification;
Protocol 1, where the vitrification solution, which contains 20% dimethylsulfoxid (DMSO), 20% ethylene glycol in MEM, supplemented with 25 mg/mL human serum albumin (HSA), is used. The ovarian cubes are to be equilibrated in 25% vitrification solution for 5 min (at 4oC), followed by equilibration in 50% vitrification solution for another 5 min (at 4oC), and finally in 100% vitrification solution for 10 min (at 4oC). Following equilibration, the ovarian cubes are to be placed on an aseptic absorbent gauze to remove the remaining vitrification solution. The cubes are then transferred to a stainless steel box, partially immersed in liquid nitrogen. Now the ovarian fragments are vitrified and are to be placed in pre-cooled cryovials for long term storage in liquid nitrogen (37).
Protocol 2, where the vitrification solution is composed of 10% dimethylsulfoxid (DMSO), and 26% ethylene glycol in MEM, supplemented with 20 mg/mL HSA, 2.5% polyvinylpyrrolidone and 1 mol/L sucrose. The ovarian cubes are to be equilibrated in 25% vitrification solution (for 5 min), then in 50% vitrification solution (for 5 min), and finally in 100% vitrification solution (for 1 min), at room temperature. After equilibration, the cubes are to be placed on an aseptic absorbent gauze at room temperature, in order to remove the remaining vitrification solution. The cubes are then to be placed in open cryostraws, and to be plunged into liquid nitrogen. Now the ovarian fragments are vitrified and are to be placed in pre-cooled cryovials for long term storage in liquid nitrogen (33, 38).
For warming of the vitrified ovarian tissue, the ovarian strips or cubes are taken out from the cryovials and placed into warming solution 1 at 37oC, which is composed of 1 mol/L sucrose in MEM, supplemented with 25 mg/mL HSA. The tissue is to be incubated in this solution for about 15 sec, and then to be transferred to the warming solution 2 (which has the same composition of warming solution 1, apart from 0.5 mol/L sucrose concentration), followed by warming solution 3 (which has the same composition of warming solution 1, apart from 0.25 mol/L sucrose concentration), and warming solution 4 (which has the same composition of warming solution 1, apart from 0 mol/L sucrose concentration), for 5 min at 37oC each (33, 37, 38).
Several studies have reported successful results of transplantation of cryopreserved ovarian tissues of both techniques, with the results of vitrification being superior or, at least, comparable to those of slow freezing (33). However, and regardless of the technique of cryopreservation, there are two major problems hindering the transplantation of the ovarian tissue and limiting the graft survival; the cryoinjury in the case of cryopreservation, and the ischemic reperfusion injury.
As the ovarian cortex is composed of tightly packed connective tissue, where it depends on the underlying highly vascular ovarian medulla for getting the necessary oxygen and nutrient supplies, it takes a relative longer time (2-3 days) to re-establish adequate vascular connections with the underlying tissue following transplantation, which leads practically to some degree of follicular atrophy and failure of long term graft survival. This is why the peritoneal grafting of the ovarian tissue has been associated with better results than the subcutaneous grafting, as the revascularization in the peritoneal case is better.
However, in all cases, a large number of follicles would be ultimately lost until the neovascularization occurs, accordingly, there would be a high risk of graft failure (39, 40). Many strategies have been tried to minimize the post-transplantation ischemic ovarian damage, however, these strategies lack the standardization, the reproducibility and the long term success (41). Examples of those strategies are:
- Mechanical induction of neoangiogenesis, through the induction of tissue injury and grafting the ovarian tissue on the being formed granulation tissue (42).
- The use of antioxidants (43-45).
- The use of neoangiogenesis-inducing growth factors (46).
- The use of hormonal therapy (47).
- The ability to efficiently cryopreserve the whole ovary, instead of the ovarian tissue fragments. The main obstacles of this procedure are the intravascular thrombosis and the inability to efficiently deliver the cryopreservation and warming solutions simultaneously to the whole ovary.
- The complexity of the surgical procedure and the ischemic reperfusion injury associated with all solid organs transplantation.
The innovative ex vivo ovary perfusion model of Shehata
In the present technique, the donor ovary, which belongs to the cancer patient herself or the matching donor for cases of ovarian failure, is removed by a laparoscopic or an open surgical approach, where the vascular pedicle of the ovary is accessed. The ovarian artery is approached as proximal as possible, and catheterized after giving off its branches. Similarly, the ovarian vein is approached as distal as possible, and catheterized before receiving its tributaries.
Now, the donor ovary can be surgically removed, while both the vascular input and output are catheterized, however, before removal, in-vivo perfusion through the catheters is to be performed for few minutes, to avoid ischemia and any risk of the microthrombi formation. The arterial and venous catheters are connected to a circuit of perfusion, composed of the following (Figure 1):
- A box to enclose the ovary and can be used as a sealed cryovial.
- The box enclosing the ovary can work as a sealed cryovial, which allows the passing of the perfusion input and output catheters during perfusion, and the complete sealing during liquid nitrogen storage
- The circuit itself is made of perfusion tubes, connected to the arterial and venous catheters.
- Reservoirs to introduce and remove the perfusates (perfusion supplemented medium, cryopreservation and warming solutions)
- A pulsatile or continues flow centrifugal pump, providing flow equivalent to the estimated physiological ovarian artery flow of the donor (pre-cryopreservation) and of the recipient (post-cryopreservation).
- A set of leukocytes and cytokines filters.
- A temperature adjustor that can control the temperature of the perfusate.
- A gas exchanger to remove CO2 and provide O2, to maintain these gases in the perfusate at the physiological levels.
The introduced procedure starts with the surgical retrieval of the donor ovary, where vascular catheterization and immediate perfusion begins. The used perfusate can vary according to the protocol used, for instance, minimal essential medium (MEM) supplemented with HSA or human tubal fluid medium supplemented with serum substitute supplement (SSS). Further supplementation could be considered according to the used protocol, such as ascorbic acid, antioxidants, hormones, growth factors, antibiotics, heparin, etc.
The immediate and continuous perfusion minimizes the risk of the microthrombi formation, however, thrombolytic medications could be supplemented to the perfusate, in order to dissolve any formed microthrombi. At this stage, the donor ovary has not manifested significant ischemia or oxygen or nutrient deprivation, and the vascular bed is clearly accessible. In case of fresh ovary transplantation, the ovary could be kept perfused under normothermic or hypothermic conditions till transplantation and intraoperative vascular anastomosis, allowing the chance of gross and or microscopic assessment of the graft, when needed. In this case, the ischemic reperfusion injury would be significantly minimized.
However, in case the cryopreservation of the ovary is planned, the cryopreservation solution (either for slow freezing or for vitrification) can be introduced into the circuit to simultaneously fill the cleaned vascular bed of the ovary and the plastic box around the graft. This ability, together with the presence of temperature adjustors, allow the application of the cryopreservation or vitrification protocol of interest (as previously described), where at the end, the graft can be stored in liquid nitrogen.
These abilities of the system allow, as well, the application of the warming protocols (as previously described), where the graft can be further perfused till the surgical transplantation, minimizing the ischemic reperfusion injury.
Figure 1. Diagrammatic representation of the ex vivo ovary perfusion system:
- A box to enclose the ovary and works as a sealed cryovial
- Ovarian vein stump connected to the circuit, using a special cannula or catheter (perfusion output)
- Ovarian artery stump connected to the circuit, using a special cannula or catheter (perfusion input)
- Reservoirs for filling the ovary-containing box with medium, the cryoprotective, vitrification, and warming solutions during cryopreservation
- The perfusion circuit
- Perfusate reservoir
- Centrifugal pump (pulsatile or continuous flow)
- Set of leukocytic and cytokines filters
- Temperature adjustor
- A gas exchanger to remove CO2 and provide O2, to maintain these gases in the perfusate at the physiological levels
- The ovary graft inside the cryovial/ perfusion box
As previously discussed, the whole ovary cryopreservation has been introduced and experimentally tested (41). In addition, the idea of ex vivo perfused ovary was used before in some experimental studies for the ex vivo culture of the whole ovary, in order to allow the ex vivo oocyte maturation and development (53). However, to the best of my knowledge, it is the first time to introduce the ex vivo perfusion technique as a procedure that should precede and follow the cryopreservation of the ovary, in order to overcome the obstacles that limit the success of the technique.
Moreover, the introduced system is very unique, allowing the application of both ex vivo perfusion and cryopreservation in one system, which ensures better and simultaneous delivery of the cryoprotective and warming solutions to the inside and the outside of the organ, allowing for better outcome of the procedure. Some advantages of the system are listed in table I.
Table I. Some advantages of the Shehata's system for ex vivo ovary perfusion and cryopreservation
Clinical applications and intended use of the proposed system
The proposed system can be applied in the following surgical and clinical interventions:
- Allogeneic ovarian transplantation, where the system will allow the ex vivo organ perfusion, minimizing the ischemic reperfusion injury and allowing graft investigation and conditioning before transplantation. In this case, the set of leukocytic and cytokine filters are included to filter the donor leukocytes and minimize the hazards of the ischemic reperfusion injury (54).
- Localized treatment of ovarian cancers without exposing the patient to the systemic hazards of chemotherapy and radiotherapy, where the affected ovary could be surgically isolated from the patient's body and circulation, and kept under perfusion in the system, while localized and highly concentrated doses of chemo- and or radiotherapy could be applied to target the cancer cells within the ovary (to preserve fertility, if some healthy tissue and follicles could survive the therapeutic techniques).
- Preservation of fertility after systemic chemotherapy or bone marrow transplantation in young females, where the ovaries could be removed before the therapy and exposed to the adequate cryopreservation provided by the system till reimplantation after the patient's survival.
- The system is also suitable for the corresponding applications on the testicles.
Conflict of interest
The intellectual properties and the system included in this manuscript belong solely to the author. All rights are preserved solely for the author. Reproduction or use of any of the included intellectual properties requires the written permission of the author. No funding was provided for the development of this work. The author welcomes funding cooperation for experimental and clinical studies.
Type of Study: Original Article |
References
1. Silber Sh. Ovarian tissue cryopreservation and transplantation: scientific implications. J Assist Reprod Genet 2016; 33: 1595-1603. [DOI:10.1007/s10815-016-0814-1]
2. Johannes O, Nouri K, Stögbauer L, Fischer EM, Lipovac M, Promberger R, et al. Ovarian tissue cryopreservation for non-malignant indications. Arch Gynecol Obstet 2010; 281: 735-739. [DOI:10.1007/s00404-009-1224-8]
3. Rodriguez-Wallberg KA, Tanbo T, Tinkanen H, Thurin-Kjellberg A, Nedstrand E, Kitlinski ML, et al. Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries- compilation of 20 years of multicenter experience. Acta Obstet Gynecol Scand 2016; 95: 1015-1026. [DOI:10.1111/aogs.12934]
4. Tsang WH, Chow KL. Cryopreservation of mammalian embryos: Advancement of putting life on hold. Birth Defects Res C Embryo Today 2010; 90: 163-175. [DOI:10.1002/bdrc.20186]
5. Santos RR, Amorim C, Cecconi S, Fassbender M, Imhof M, Lornage J, et al. Cryopreservation of ovarian tissue: an emerging technology for female germline preservation of endangered species and breeds. Anim Reprod Sci 2010; 122: 151-163. [DOI:10.1016/j.anireprosci.2010.08.010]
6. Silber SJ. Ovary cryopreservation and transplantation for fertility preservation. Mol Hum Reprod 2012; 18: 59-67. [DOI:10.1093/molehr/gar082]
7. Candy CJ, Wood MJ, Whittingham DG. Follicular development in cryopreserved marmoset ovarian tissue after transplantation. Hum Reprod 1995; 10: 2334-2338. [DOI:10.1093/oxfordjournals.humrep.a136295]
8. Kardak A, Leibo SP, Devireddy R. Membrane transport properties of equine and macaque ovarian tissues frozen in mixtures of dimethylsulfoxide and ethylene glycol. J Biomech Eng 2007; 129: 688-694. [DOI:10.1115/1.2768107]
9. Li G, Thirumala S, Leibo SP, Devireddy RV. Subzero water transport characteristics and optimal rates of freezing rhesus monkey (Macaca mulatta) ovarian tissue. Mol Reprod Dev 2006; 73: 1600-1611. [DOI:10.1002/mrd.20541]
10. Schnorr J, Oehninger S, Toner J, Hsiu J, Lanzendorf S, Williams R, et al. Functional studies of subcutaneous ovarian transplants in non-human primates: steroidogenesis, endometrial development, ovulation, menstrual patterns and gamete morphology. Hum Reprod 2002; 17: 612-619. [DOI:10.1093/humrep/17.3.612]
11. Ting AY, Yeoman RR, Lawson MS, Zelinski MB. In vitro development of secondary follicles from cryopreserved rhesus macaque ovarian tissue after slow-rate freeze or vitrification. Hum Reprod 2011; 26: 2461-2472. [DOI:10.1093/humrep/der196]
12. Von Schönfeldt V, Chandolia R, Kiesel L, Nieschlag E, Schlatt S, Sonntag B. Advanced follicle development in xenografted prepubertal ovarian tissue: the common marmoset as a nonhuman primate model for ovarian tissue transplantation. Fertil Steril 2011; 95: 1428-1434. [DOI:10.1016/j.fertnstert.2010.11.003]
13. Von Schönfeldt V, Chandolia R, Kiesel L, Nieschlag E, Schlatt S, Sonntag B. Assessment of follicular development in cryopreserved primate ovarian tissue by xenografting: prepubertal tissues are less sensitive to the choice of cryoprotectant. Reproduction 2011; 141: 481-490. [DOI:10.1530/REP-10-0454]
14. Yeoman RR, Wolf DP, Lee DM. Coculture of monkey ovarian tissue increases survival after vitrification and slow-rate freezing. Fertil Steril 2005; 83 (Suppl.): 1248-1254. [DOI:10.1016/j.fertnstert.2004.11.036]
15. Amorim CA, Jacobs S, Devireddy RV, Van Langendonckt A, Vanacker J, Jaeger J, et al. Successful vitrification and autografting of baboon (Papio anubis) ovarian tissue. Hum Reprod 2013; 28: 2146-2156. [DOI:10.1093/humrep/det103]
16. Hasegawa A, Mochida N, Ogasawara T, Koyama K. Pup birth from mouse oocytes in preantral follicles derived from vitrified and warmed ovariesfollowed by in vitro growth, in vitro maturation, and in vitro fertilization. Fertil Steril 2006; 86: 1182-1192. [DOI:10.1016/j.fertnstert.2005.12.082]
17. Hashimoto S, Suzuki N, Yamanaka M, Hosoi Y, Ishizuka B, Morimoto Y. Effects of vitrification solutions and equilibration times on the morphology of cynomolgus ovarian tissues. Reprod Biomed Online 2010; 21: 501-509. [DOI:10.1016/j.rbmo.2010.04.029]
18. Kagabu S, Umezu M. Transplantation of cryopreserved mouse, Chinese hamster, rabbit, Japanese monkey and rat ovaries into rat recipients. Exp Anim 2000; 49: 17-21. [DOI:10.1538/expanim.49.17]
19. Suzuki N, Hashimoto S, Igarashi S, Takae S, Yamanaka M, Yamochi T, et al. Assessment of long-term function of heterotopic transplants of vitrified ovarian tissue in cynomolgus 1 monkeys. Hum Reprod 2012; 27: 2420-2429. [DOI:10.1093/humrep/des178]
20. Ting AY, Yeoman RR, Campos JR, Lawson MS, Mullen SF, Fahy GM, et al. Morphological and functional preservation of pre-antral follicles after vitrification of macaque ovarian tissue in a closed system. Hum Reprod 2013; 28: 1267-1279. [DOI:10.1093/humrep/det032]
21. Ting AY, Yeoman RR, Lawson MS, Zelinski MB. In vitro development of secondary follicles from cryopreserved rhesus macaque ovarian tissue after slow-rate freeze or vitrification. Hum Reprod 2011; 26: 2461-2472. [DOI:10.1093/humrep/der196]
22. Ting AY, Yeoman RR, Lawson MS, Zelinski MB. Synthetic polymers improve vitrification outcomes of macaque ovarian tissue as assessed by histological integrity and the in vitro development of secondary follicles. Cryobiology 2012; 65: 1-11. [DOI:10.1016/j.cryobiol.2012.04.005]
23. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005; 83: 1622-1628. [DOI:10.1016/j.fertnstert.2005.03.013]
24. Prest SJ, May FE, Westley BR. The estrogen-regulated protein, TFF-1, stimulates migration of human breast cancer cells. FASEB J 2002; 1: 592-594. [DOI:10.1096/fj.01-0498fje]
25. Seli E, Tangir J. Fertility preservation options for female patients with malignancies. Curr Opin Obstet Gynecol 2005; 17: 299-308. [DOI:10.1097/01.gco.0000169108.15623.34]
26. Fauser B. Follicle pool depletion: factors involved and implications. Fertil Steril 2000; 74: 629-630. [DOI:10.1016/S0015-0282(00)01530-2]
27. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agent on human primordial follicle reserve. Cancer Res 2007; 67: 10159-10162. [DOI:10.1158/0008-5472.CAN-07-2042]
28. Practice Committee of American Society for Reproductive Medicine; Practice Committee of Society for Assisted Reproductive Technology. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2008; 90: 241-246. [DOI:10.1016/j.fertnstert.2008.08.039]
29. Silber S, Gosden RG. Ovarian transplantation in a series of monozygotic twins discordant for ovarian failure. N Engl J Med 2007; 356: 1382-1384. [DOI:10.1056/NEJMc066574]
30. Silber S, Kagawa N, Kuwayama M, Gosden R. Duration of fertility after fresh and frozen ovary transplantation. Fertil Steril 2010; 94: 2191-2196. [DOI:10.1016/j.fertnstert.2009.12.073]
31. Vutyavanich T, Piromlertamorn W, Nunta S. Rapid freezing versus slow programmable freezing of human spermatozoa. Fertil Steril 2010; 93: 1921-1928. [DOI:10.1016/j.fertnstert.2008.04.076]
32. Karlsson JO, Szurek EA, Higgins AZ, Lee SR, and Eroglu A. Optimization of cryoprotectant loading into murine and human oocytes. Cryobiology 2014; 68: 18-28. [DOI:10.1016/j.cryobiol.2013.11.002]
33. Amorim CA, Dolmans MM, David A, Jaeger J, Vanacker J, Camboni A, et al. Vitrification and xenografting of human ovarian tissue. Fertil Steril 2012; 98: 1291-1298. [DOI:10.1016/j.fertnstert.2012.07.1109]
34. Kuleshova, L.L. and Lopata, A. Vitrification can be more favorable than slow cooling. Fertil Steril 2002; 78: 449-454. [DOI:10.1016/S0015-0282(02)03305-8]
35. Varisli O, Scott H, Agca C, and Agca Y. The effects of cooling rates and type of freezing extenders on cryosurvival of rat sperm. Cryobiology 2013; 67: 109-116. [DOI:10.1016/j.cryobiol.2013.05.009]
36. van Eyck AS, Jordan BF, Gallez B, Heilier JF, van Langendonckt A, Donnez J. Electron paramagnetic resonance as a tool to evaluate human ovarian tissue reoxygenation after xenografting. Fertil Steril 2009; 92: 374-381. [DOI:10.1016/j.fertnstert.2008.05.012]
37. Keros V, Xella S, Hultenby K, Pettersson K, Sheikhi M, Volpe A, et al. Vitrification versus controlled-rate freewing in cryopreservation of human ovarian tissue. Hum Reprod 2009; 24: 1670-1683. [DOI:10.1093/humrep/dep079]
38. Huang L, Mo Y, Wang W, Li Y, Zhang Q, Yang D. Cryopreservation of human ovarian tissue by solid-surface vitrification. Eur J Obstet Gynecol Reprod Biol 2008; 139: 193-198. [DOI:10.1016/j.ejogrb.2008.03.002]
39. Liu J, Van der Elst J, Van den Broecke R, et al. Early massive follicle loss and apoptosis in heterotopically grafted newborn mouse ovaries. Hum Reprod 2002; 17: 605-611. [DOI:10.1093/humrep/17.3.605]
40. Bedaiwy MA, El Nashar SA, Ali M El Saman, Johannes LH Evers, Samith Sandadi, Nina Desai, et al. Reproductive outcome after transplantation of ovarian tissue: a systematic review. Hum Reprod 2008; 23: 2709-2717. [DOI:10.1093/humrep/den301]
41. Bedaiwy MA, Falcone T. Whole ovary transplantation. Clin Obstet Gynecol 2010; 53: 797-803. [DOI:10.1097/GRF.0b013e3181f97c94]
42. Israely T, Nevo N, Harmelin A, et al. Reducing ischaemic damage in rodent ovarian xenografts transplanted into granulation tissue. Hum Reprod 2006; 21: 1368-1379. [DOI:10.1093/humrep/del010]
43. Kim SS, Yang HW, Kang HG, Lee HH, Lee HC, Ko DS, et al. Quantitative assessment of ischemic tissue damage in ovarian cortical tissue with or without antioxidant (ascorbic acid) treatment. Fertil Steril 2004; 82: 679-685. [DOI:10.1016/j.fertnstert.2004.05.022]
44. Sagsoz N, Kisa U, Apan A. Ischaemia-reperfusion injury of rat ovary and the effects of vitamin C, mannitol and verapamil. Hum Reprod 2002; 17: 2972-2976. [DOI:10.1093/humrep/17.11.2972]
45. Sapmaz E, Ayar A, Celik H, Sapmaz T, Kilic N and Yasar MA. Effects of melatonin and oxytetracycline in autologous intraperitoneal ovary transplantation in rats. Neuro Endocrinol Lett 2003; 24: 350-354.
46. Schnorr J, Oehninger S, Toner J, Hsiu J, Lanzendorf S, Williams R, et al. Functional studies of subcutaneous ovarian transplants in non-human primates: steroidogenesis, endometrial development, ovulation, menstrual patterns and gamete morphology. Hum Reprod 2002; 17: 612-619. [DOI:10.1093/humrep/17.3.612]
47. Imthurn B, Cox SL, Jenkin G, Trounson AO, Shaw JM. Gonadotrophin administration can benefit ovarian tissue grafted to the body wall: implications for human ovarian grafting. Mol Cell Endocrinol 2000; 163: 141-146. [DOI:10.1016/S0303-7207(00)00218-5]
48. Jeremias E, Bedaiwy MA, Gurunluoglu R, Biscotti CV, Siemionow M and Falcone T. Heterotopic autotransplantation of the ovary with microvascular anastomosis: a novel surgical technique. Fertil Steril 2002; 77: 1278-1282. [DOI:10.1016/S0015-0282(02)03110-2]
49. Jadoul P, Donnez J, Dolmans MM, Squifflet J, Lengele B and Martinez-Madrid B. Laparoscopic ovariectomy for whole human ovary cryopreservation: technical aspects. Fertil Steril 2007; 87: 971-975. [DOI:10.1016/j.fertnstert.2006.10.012]
50. Silber SJ, Grudzinskas G, Gosden RG. Successful pregnancy after microsurgical transplantation of an intact ovary. N Engl J Med 2008; 359: 2617-2618. [DOI:10.1056/NEJMc0804321]
51. Courbiere B, Caquant L, Mazoyer C, Franck M, Lornage J, Salle B. Difficulties improving ovarian functional recovery by microvascular transplantation and whole ovary vitrification. Fertil Steril 2009; 91: 2697-2706. [DOI:10.1016/j.fertnstert.2008.03.012]
52. Onions VJ, Webb R, McNeilly AS, Campbell BK. Ovarian endocrine profile and long-term vascular patency following heterotopic autotransplantation of cryopreserved whole ovine ovaries. Hum Reprod 2009; 24: 2845-2855. [DOI:10.1093/humrep/dep274]
53. Maffei S, Galeati G, Pennarossa G, Brevini TA, Gandolfi F. Extended ex vivo culture of fresh and cryopreserved whole sheep ovaries. Reprod Fertil Dev 2015; 28: 1893-1903. [DOI:10.1071/RD15101]
54. Mohamed SA Mohamed Translational insights on lung transplantation; learning from immunology. Iran J Immunol 2015; 12: 156-65.
55. Khazaie H, Rezaie L, Payam NR, Najafi F. Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial. Gen Hosp Psychiatry 2015; 37: 40-45. [DOI:10.1016/j.genhosppsych.2014.10.010]
56. Khin NA, Kronstein PD, Yang P, Ishida E, Hung HJ, Mathis MV, et al. Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials. J Clin Psychiatry 2015; 76: 1060-1063. [DOI:10.4088/JCP.14cs09700]
57. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380: 2224-2260. [DOI:10.1016/S0140-6736(12)61766-8]
58. Van Thiel D, Gavaler JS, Cobb CF, Graham TO. Ethanol, a Leydig cell toxin: evidence obtained in vivo and in vitro. Pharmacol Biochem Behav 1983; 18: 317-323. [DOI:10.1016/0091-3057(83)90193-4]
59. Salonen I, Eriksson C. Penetration of ethanol into the male reproductive tract. Alcoholism: Clin Exp Res 1989; 13: 746-751. [DOI:10.1111/j.1530-0277.1989.tb00414.x]
60. Komiya A, Kato T, Kawauchi Y, Watanabe A, Fuse H. Clinical factors associated with sperm DNA fragmentation in male patients with infertility. Sci World J 2014; 2014: 868303. [DOI:10.1155/2014/868303]
61. Talebi AR, Sarcheshmeh AA, Khalili MA, Tabibnejad N. Effects of ethanol consumption on chromatin condensation and DNA integrity of epididymal spermatozoa in rat. Alcohol 2011; 45: 403-409. [DOI:10.1016/j.alcohol.2010.10.005]
62. Rahimipour M, Talebi AR, Anvari M, Sarcheshmeh AA, Omidi M. Effects of different doses of ethanol on sperm parameters, chromatin structure and apoptosis in adult mice. Eur J Obstet Gynecol Reprod Biol 2013; 170: 423-428. [DOI:10.1016/j.ejogrb.2013.06.038]
63. Eid NA, Shibata MA, Ito Y, Kusakabe K, Hammad H, Otsuki Y. Involvement of Fas system and active caspases in apoptotic signalling in testicular germ cells of ethanol‐treated rats. Int J Androl 2002; 25: 159-167. [DOI:10.1046/j.1365-2605.2002.00341.x]
64. Ouko LA, Shantikumar K, Knezovich J, Haycock P, Schnugh DJ, Ramsay M. Effect of Alcohol Consumption on CpG Methylation in the Differentially Methylated Regions of H19 and IG‐DMR in Male Gametes- Implications for Fetal Alcohol Spectrum Disorders. Alcoholism: Clin Exp Res 2009; 33: 1615-1627. [DOI:10.1111/j.1530-0277.2009.00993.x]
65. Wu D, Cederbaum AI. Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003; 27: 277-284.
66. Amanvermez R, Demir S, Tunçel ÖK, Alvur M, Agar E. Alcohol-induced oxidative stress and reduction in oxidation by ascorbate/L-cys/L-met in the testis, ovary, kidney, and lung of rat. Adv Ther 2005; 22: 548-558. [DOI:10.1007/BF02849949]
67. Cacciola G, Chioccarelli T, Ricci G, Meccariello R, Fasano S, Pierantoni R, et al. The endocannabinoid system in vertebrate male reproduction: a comparative overview. Mol Cell Endocrinol 2008; 286: S24-S30. [DOI:10.1016/j.mce.2008.01.004]
68. Pasqualotto FF, Sharma RK, Nelson DR, Thomas AJ, Agarwal A. Relationship between oxidative stress, semen characteristics, and clinical diagnosis in men undergoing infertility investigation. Fertil Steril 2000; 73: 459-464. [DOI:10.1016/S0015-0282(99)00567-1]
69. Song B-J, Moon K-H, Upreti VV, Eddington ND, Lee IJ. Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage. Curr Pharm Biotechnol 2010; 11: 434-443. [DOI:10.2174/138920110791591436]
70. Barenys M, Macia N, Camps L, de Lapuente J, Gomez-Catalan J, Gonzalez-Linares J, et al. Chronic exposure to MDMA (ecstasy) increases DNA damage in sperm and alters testes histopathology in male rats. Toxicol Lett 2009; 191: 40-46. [DOI:10.1016/j.toxlet.2009.08.002]
71. Battista N, Pasquariello N, Di Tommaso M, Maccarrone M. Interplay between endocannabinoids, steroids and cytokines in the control of human reproduction. J Neuroendocrinol 2008; 20: 82-89. [DOI:10.1111/j.1365-2826.2008.01684.x]
72. Fronczak CM, Kim ED, Barqawi AB. The insults of illicit drug use on male fertility. J Androl 2012; 33: 515-528. [DOI:10.2164/jandrol.110.011874]
73. Safarinejad MR, Asgari SA, Farshi A, Ghaedi G, Kolahi AA, Iravani S, et al. The effects of opiate consumption on serum reproductive hormone levels, sperm parameters, seminal plasma antioxidant capacity and sperm DNA integrity. Reprod Toxicol 2013; 36: 18-23. [DOI:10.1016/j.reprotox.2012.11.010]
74. Wyrobek AJ, Eskenazi B, Young S, Arnheim N, Tiemann-Boege I, Jabs E, et al. Advancing age has differential effects on DNA damage, chromatin integrity, gene mutations, and aneuploidies in sperm. Proc Nat Acad Sci 2006; 103: 9601-9606. [DOI:10.1073/pnas.0506468103]
75. Eskenazi B, Wyrobek AJ, Sloter E, Kidd S, Moore L, Young S, et al. The association of age and semen quality in healthy men. Hum Reprod 2003; 18: 447-454. [DOI:10.1093/humrep/deg107]
76. Pasqualotto FF, Sobreiro BP, Hallak J, Pasqualotto EB, Lucon AM. Sperm concentration and normal sperm morphology decrease and follicle‐stimulating hormone level increases with age. BJU Int 2005; 96: 1087-1091. [DOI:10.1111/j.1464-410X.2005.05806.x]
77. Morris I, Ilott S, Dixon L, Brison D. The spectrum of DNA damage in human sperm assessed by single cell gel electrophoresis (Comet assay) and its relationship to fertilization and embryo development. Hum Reprod 2002; 17: 990-998. [DOI:10.1093/humrep/17.4.990]
78. Angelopoulou R, Plastira K, Msaouel P. Spermatozoal sensitive biomarkers to defective protaminosis and fragmented DNA. Reprod Biol Endocrinol 2007; 5: 36. [DOI:10.1186/1477-7827-5-36]
79. Youssry M, Ozmen B, Orief Y, Zohni K, Al-Hasani S. Human sperm DNA damage in the context of assisted reproductive techniques. Iran J Reprod Med 2007; 5: 137-150.
80. Moskovtsev SI, Willis J, Mullen JBM. Age-related decline in sperm deoxyribonucleic acid integrity in patients evaluated for male infertility. Fertil Steril 2006; 85: 496-499. [DOI:10.1016/j.fertnstert.2005.05.075]
81. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003; 17: 1195-1214. [DOI:10.1096/fj.02-0752rev]
82. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996; 313: 17-29. [DOI:10.1042/bj3130017]
83. Alexeyev MF. Is there more to aging than mitochondrial DNA and reactive oxygen species? FEBS J 2009; 276: 5768-5787. [DOI:10.1111/j.1742-4658.2009.07269.x]
84. Carrell DT. Paternal influences on human reproductive success: Cambridge University Press; 2013. [DOI:10.1017/CBO9781139169349]
85. Barroso G, Morshedi M, Oehninger S. Analysis of DNA fragmentation, plasma membrane translocation of phosphatidylserine and oxidative stress in human spermatozoa. Hum Reprod 2000; 15: 1338-1344. [DOI:10.1093/humrep/15.6.1338]
86. Cocuzza M, Athayde KS, Agarwal A, Sharma R, Pagani R, Lucon AM, et al. Age-related increase of reactive oxygen species in neat semen in healthy fertile men. Urology 2008; 71: 490-494. [DOI:10.1016/j.urology.2007.11.041]
87. Potts J, Pasqualotto F. Seminal oxidative stress in patients with chronic prostatitis. Andrologia 2003; 35: 304-308. [DOI:10.1111/j.1439-0272.2003.tb00862.x]
88. de La Rochebrochard E, Thonneau P. Paternal age and maternal age are risk factors for miscarriage; results of a multicentre European study. Hum Reprod 2002; 17: 1649-1656. [DOI:10.1093/humrep/17.6.1649]
89. Schmid T, Eskenazi B, Baumgartner A, Marchetti F, Young S, Weldon R, et al. The effects of male age on sperm DNA damage in healthy non-smokers. Hum Reprod 2007; 22: 180-187. [DOI:10.1093/humrep/del338]
90. Azam S, Hadi N, Khan NU, Hadi SM. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med Sci Monitor 2003; 9: BR325-BR330.
91. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999; 59: 4375-4382.
92. Dupont C, Faure C, Sermondade N, Boubaya M, Eustache F, Clément P, et al. Obesity leads to higher risk of sperm DNA damage in infertile patients. Asian J Androl 2013; 15: 622-625. [DOI:10.1038/aja.2013.65]
93. Kort HI, Massey JB, Elsner CW, Mitchell‐Leef D, Shapiro DB, Witt MA, et al. Impact of body mass index values on sperm quantity and quality. J Androl 2006; 27: 450-452. [DOI:10.2164/jandrol.05124]
94. Tamburrino L, Marchiani S, Montoya M, Elia Marino F, Natali I, Cambi M, et al. Mechanisms and clinical correlates of sperm DNA damage. Asian J Androl 2012; 14: 24-31. [DOI:10.1038/aja.2011.59]
95. Gandhi G, Kaur G. Assessment of DNA damage in obese individuals. Res J Biol 2012; 2: 37-44.
96. Tunc O, Bakos H, Tremellen K. Impact of body mass index on seminal oxidative stress. Andrologia 2011; 43: 121-128. [DOI:10.1111/j.1439-0272.2009.01032.x]
97. Rybar R, Kopecka V, Prinosilova P, Markova P, Rubes J. Male obesity and age in relationship to semen parameters and sperm chromatin integrity. Andrologia 2011; 43: 286-291. [DOI:10.1111/j.1439-0272.2010.01057.x]
98. Momeni HR, Eskandari N. Effect of vitamin E on sperm parameters and DNA integrity in sodium arsenite-treated rats. Iran J Reprod Med 2012; 10: 249-256.
99. Sabeti P, Pourmasumi S, Rahiminia T, Akyash F, Talebi AR. Etiologies of sperm oxidative stress. Int J Reprod BioMed 2016; 14: 231-240.
100. Agarwal A, Nallella KP, Allamaneni SS, Said TM. Role of antioxidants in treatment of male infertility: an overview of the literature. Reprod Biomed Online 2004; 8: 616-627. [DOI:10.1016/S1472-6483(10)61641-0]
101. Silver EW, Eskenazi B, Evenson DP, Block G, Young S, Wyrobek AJ. Effect of antioxidant intake on sperm chromatin stability in healthy nonsmoking men. J Androl 2005; 26: 550-556. [DOI:10.2164/jandrol.04165]
102. Sen S, Chakraborty R. The role of antioxidants in human health. Oxidative stress: diagnostics, prevention, and therapy. 2011;1083:1-37. [DOI:10.1021/bk-2011-1083.ch001]
103. Wyrobek AJ. Methods and concepts in detecting abnormal reproductive outcomes of paternal origin. Reprod Toxicol 1993; 7: 3-16. [DOI:10.1016/0890-6238(93)90064-E]
104. Gupta C. Reproductive malformation of the male offspring following maternal exposure to estrogenic chemicals. Proc Soc Exp Biol Med 2000; 224: 61-68. [DOI:10.1046/j.1525-1373.2000.22402.x]
105. Meeker JD, Hauser R. Exposure to polychlorinated biphenyls (PCBs) and male reproduction. Syst Biol Reprod Med 2010; 56: 122-131. [DOI:10.3109/19396360903443658]
106. Aktar W, Sengupta D, Chowdhury A. Impact of pesticides use in agriculture: their benefits and hazards. Interdiscip Toxicol 2009; 2: 1-12. [DOI:10.2478/v10102-009-0001-7]
107. Roeleveld N, Bretveld R. The impact of pesticides on male fertility. Curr Opin Obstet Gynecol 2008; 20: 229-233. [DOI:10.1097/GCO.0b013e3282fcc334]
108. Control CfD, Prevention. Chemistry and Toxicology of Cigarette Smoke and Biomarkers of Exposure and Harm. 2010.
109. Eftekhar M, Pourmasumi S, Sabeti P, Mirhosseini F. Relation of Second Hand Smoker and Effect on Pregnancy Outcome and Newborns Parameters. Womens Health Gynecol 2016; 6: 2.
110. Arabi M, Moshtaghi H. Influence of cigarette smoking on spermatozoa via seminal plasma. Andrologia 2005; 37: 119-124. [DOI:10.1111/j.1439-0272.2005.00664.x]
111. Briviba K, Kulling SE, Möseneder J, Watzl B, Rechkemmer G, Bub A. Effects of supplementing a low-carotenoid diet with a tomato extract for 2 weeks on endogenous levels of DNA single strand breaks and immune functions in healthy non-smokers and smokers. Carcinogenesis 2004; 25: 2373-2378. [DOI:10.1093/carcin/bgh249]
112. Künzle R, Mueller MD, Hänggi W, Birkhäuser MH, Drescher H, Bersinger NA. Semen quality of male smokers and nonsmokers in infertile couples. Fertil Steril 2003; 79: 287-291. [DOI:10.1016/S0015-0282(02)04664-2]
113. Calogero A, Polosa R, Perdichizzi A, Guarino F, La Vignera S, Scarfia A, et al. Cigarette smoke extract immobilizes human spermatozoa and induces sperm apoptosis. Reprod Biomed Online 2009; 19: 564-571. [DOI:10.1016/j.rbmo.2009.05.004]
114. Saleh RA, Agarwal A, Sharma RK, Nelson DR, Thomas AJ. Effect of cigarette smoking on levels of seminal oxidative stress in infertile men: a prospective study. Fertil Steril 2002; 78: 491-499. [DOI:10.1016/S0015-0282(02)03294-6]
115. Potts R, Newbury C, Smith G, Notarianni L, Jefferies T. Sperm chromatin damage associated with male smoking. Mutat Res 1999; 423: 103-111. [DOI:10.1016/S0027-5107(98)00242-5]
116. Yu B, Qi Y, Liu D, Gao X, Chen H, Bai C, et al. Cigarette smoking is associated with abnormal histone-to-protamine transition in human sperm. Fertil Steril 2014; 101: 51-57. [DOI:10.1016/j.fertnstert.2013.09.001]
117. Hamad M, Shelko N, Kartarius S, Montenarh M, Hammadeh M. Impact of cigarette smoking on histone (H2B) to protamine ratio in human spermatozoa and its relation to sperm parameters. Andrology 2014; 2: 666-677. [DOI:10.1111/j.2047-2927.2014.00245.x]
118. Pembrey ME, Bygren LO, Kaati G, Edvinsson S, Northstone K, Sjöström M, et al. Sex-specific, male-line transgenerational responses in humans. Eur J Hum Genet 2006; 14: 159-166. [DOI:10.1038/sj.ejhg.5201538]
119. Olshan AF, Faustman EM. Male-mediated developmental toxicity. Reprod Toxicol 1993; 7: 191-202. [DOI:10.1016/0890-6238(93)90224-U]
120. Mailankot M, Kunnath AP, Jayalekshmi H, Koduru B, Valsalan R. Radio frequency electromagnetic radiation (RF-EMR) from GSM (0.9/1.8 GHz) mobile phones induces oxidative stress and reduces sperm motility in rats. Clinics 2009; 64: 561-565. [DOI:10.1590/S1807-59322009000600011]
121. Falzone N, Huyser C, Becker P, Leszczynski D, Franken DR. The effect of pulsed 900‐MHz GSM mobile phone radiation on the acrosome reaction, head morphometry and zona binding of human spermatozoa. Int J Androl 2011; 34: 20-26. [DOI:10.1111/j.1365-2605.2010.01054.x]
122. Sivani S, Sudarsanam D. Impacts of radio-frequency electromagnetic field (RF-EMF) from cell phone towers and wireless devices on biosystem and ecosystem-a review. Biol Med 2012; 4: 202-216.
123. Adams JA, Galloway TS, Mondal D, Esteves SC, Mathews F. Effect of mobile telephones on sperm quality: A systematic review and meta-analysis. Environment Int 2014; 70: 106-112. [DOI:10.1016/j.envint.2014.04.015]
124. De Rosa M, Zarrilli S, Paesano L, Carbone U, Boggia B, Petretta M, et al. Traffic pollutants affect fertility in men. Hum Reprod 2003; 18: 1055-1061. [DOI:10.1093/humrep/deg226]
125. Boggia B, Carbone U, Farinaro E, Zarrilli S, Lombardi G, Colao A, et al. Effects of working posture and exposure to traffic pollutants on sperm quality. J Endocrinol Invest 2009; 32: 430-434. [DOI:10.1007/BF03346481]
126. Calogero AE, La Vignera S, Condorelli RA, Perdichizzi A, Valenti D, Asero P, et al. Environmental car exhaust pollution damages human sperm chromatin and DNA. J Endocrinol Invest 2011; 34: 139-143. [DOI:10.1007/BF03346722]
127. Rubes J, Selevan SG, Evenson DP, Zudova D, Vozdova M, Zudova Z, et al. Episodic air pollution is associated with increased DNA fragmentation in human sperm without other changes in semen quality. Hum Reprod 2005; 20: 2776-2783. [DOI:10.1093/humrep/dei122]
128. Ji G, Gu A, Zhou Y, Shi X, Xia Y, Long Y, et al. Interactions between exposure to environmental polycyclic aromatic hydrocarbons and DNA repair gene polymorphisms on bulky DNA adducts in human sperm. PLoS One 2010; 5: pii: e13145. [DOI:10.1371/journal.pone.0013145]
129. Rubes J, Rybar R, Prinosilova P, Veznik Z, Chvatalova I, Solansky I, et al. Genetic polymorphisms influence the susceptibility of men to sperm DNA damage associated with exposure to air pollution. Mutat Res 2010; 683: 9-15. [DOI:10.1016/j.mrfmmm.2009.09.010]
130. Pacey AA. Environmental and lifestyle factors associated with sperm DNA damage. Hum Fertil 2010; 13: 189-193. [DOI:10.3109/14647273.2010.531883]
131. Horak S, Polanska J, Widlak P. Bulky DNA adducts in human sperm: relationship with fertility, semen quality, smoking, and environmental factors. Mutat Res 2003; 537: 53-65. [DOI:10.1016/S1383-5718(03)00051-2]
132. Jung A, Schuppe HC. Influence of genital heat stress on semen quality in humans. Andrologia 2007; 39: 203-215. [DOI:10.1111/j.1439-0272.2007.00794.x]
133. 1Banks S, King SA, Irvine DS, Saunders PT. Impact of a mild scrotal heat stress on DNA integrity in murine spermatozoa. Reproduction 2005; 129: 505-514 [DOI:10.1530/rep.1.00531]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
